ICON plc: ICON Reports Third Quarter 2026 Results

ICON plc reported Q3 2026 results with revenue of $2.02B, adjusted EBITDA of $336.9M, and net income of $122.1M. The company had net business wins of $3.15B and a book-to-bill ratio of 1.56x. ICON repurchased $400M in stock and updated its 2026 guidance, expecting revenue between $8.1B and $8.2B and adjusted EPS between $10.35 and $10.65.

Original reporting
Published Oct 27, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ICLR
Bullish
high confidence
Mentioned
$ICLR
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ICLRBullishHigh
01

Why it matters

The earnings release provides fresh guidance and a sizable share buyback, offering a clear catalyst for short‑term trading.

02

Market read

First‑time disclosure of earnings and guidance creates a material trading opportunity.

03

What to watch

High share repurchase activity may limit cash for growth initiatives.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

ICON plc is a Dublin‑based clinical research organization listed on NASDAQ.

Company-level read

Ticker impact

$ICLRBullishHigh confidence
Context

Q3 2026 earnings and updated full-year guidance were disclosed for the first time.

Expected impact

likely modest upside as market prices in higher full-year revenue and EPS guidance

Evidence & confidence

The company reported a $2.0B revenue, adjusted EBITDA of $336.9M and raised FY2026 revenue guidance to $8.1-$8.2B, providing fresh positive material.

Market effects

Strong results may boost sentiment in the clinical research services sector.

Positive for European biotech and CRO stocks.

Limited to investors tracking CRO earnings and guidance.

Counterpoint

Revenue decline and lower margins could signal underlying demand weakness.

Key entities

  • ICON plc

    Clinical research organization reporting Q3 2026 results.

Related articles

$ICLRMed

Icon PLC (ICLR) (Q3 2026) Earnings Call Highlights: Record

Icon PLC (ICLR) reported Q3 2026 revenue of $2B, down 2.9% YoY. Direct fee revenue growth remains modest, and cancellations are slightly above average. Gross margin improved 90 bps sequentially, and adjusted EBITDA margin rose to 16.6%. The company expects Q4 SG&A expenses to increase and faces ongoing pricing pressure. Management anticipates mid-single-digit revenue growth and higher single-digit earnings growth in 2027, with formal guidance to be provided in Q4.

$ICLRHighAI 8/10

ICLR Stock Jumps As Guidance And Backlog Impress Wall Street

ICON plc (NASDAQ: ICLR) stock rose 16.39% on October 28, 2026, after beating Q3 earnings expectations and raising 2026 revenue guidance to $8.10B–$8.20B. The company reported adjusted EPS of $2.66 and revenue of $2.02B, with a record backlog and $400M in share repurchases. Analysts have mixed reactions, with upgrades from Bank of America and RBC, while UBS remains cautious.

$ICLRHighAI 8/10

ICLR Stock Jumps As Earnings Beat And Guidance Rise

ICON plc (ICLR) stock rose 11.54% after Q3 earnings beat expectations, with revenue of $2.02B and EPS of $2.66. The company raised full-year guidance, citing strong demand and a record backlog. Analysts have mixed views, with some upgrading and others warning of risks. ICLR trades at a premium multiple, with technical indicators showing strong momentum.